Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World August 19, 2013 Hepeng Jia	Chinese drug watchdog set for major reforms China's slow drug approval process has been a cause for complaint for both Chinese subsidiaries of multinational pharmaceuticals and domestic drug developers.
Chemistry World July 13, 2007 Hepeng Jia	Chinese Legislation to Increase Drug Safety A long-awaited amendment to China's drug registration system is expected to discipline the country's medical sector and boost the pharmaceutical industry.
Pharmaceutical Executive October 1, 2011	30 Years of Pharma: Perspective in Numbers, Part 3 Top 10 generics companies.
Chemistry World May 8, 2008 Hepeng Jia	China to fast track pioneering drugs China is to speed up the approval of groundbreaking new drugs in an effort to encourage innovation in its pharmaceutical sector, a State Food and Drug Administration (SFDA) official has revealed.
Managed Care February 2008 Martin Sipkoff	FDA Approach to Generics May Be a Mixed Blessing A recently announced initiative is supposed to speed approval of generic drugs, but does it address some fundamental flaws in the approval process?
Pharmaceutical Executive August 1, 2013 William Looney	Breaching the Great Wall With a revision of China's basic drug approval law now underway, a multinational team of experts is proposing major changes to make the country a world class player in innovation.
Chemistry World October 11, 2007 Hepeng Jia	China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
The Motley Fool July 29, 2010 Brian Orelli	Buy, Sell, or Hold: Biotech Generics Generic biotech drugs are coming. Hop on.
Pharmaceutical Executive February 1, 2006 Sarah Houlton	Global Report: Moving Towards Generic Biologics The European Medicines Agency hopes to complete its guidelines for the approval of biosimilar drugs early this year, paving the way for the approval of biogenerics - and a potential goldmine for the generics companies.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
BusinessWeek November 3, 2003 Diane Brady	Biotech: Teva's Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
Chemistry World February 14, 2012 Rebecca Trager	FDA proposes biosimilars approval pathway The US Food and Drug Administration has released its long awaited guidance to assist in the development and approval of so-called 'biosimilars' - biological drugs that are very similar to licensed ones.
The Motley Fool February 23, 2007 Rich Duprey	Foolish Forecast: Barr Labs Resets Bar The pharmaceutical is set to release fourth-quarter 2006 financial results. Investors, here is what you can expect to see.
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.
The Motley Fool June 25, 2007 Brian Orelli	Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
Chemistry World May 18, 2007 Hepeng Jia	China's Battle with Fake Drugs While China's pharmaceutical industry is experiencing rapid growth, a boom in counterfeit drugs is costing human lives and eroding the public's confidence in medical products.
Managed Care January 2007 Martin Sipkoff	Employers Want Plans & PBMs To Push Hard for Generics Health insurers' aggressive stand on members' use of generic drugs can attract new clients, but does it interfere with the physician-patient relationship?
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Chemistry World November 21, 2008 Pete Mitchell	UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
Managed Care September 2007 Martin Sipkoff	Patent Law Rulings Work in Favor of Generics Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share.
Pharmaceutical Executive October 1, 2012 Jill Wechsler	Changes and Challenges at FDA New user fee programs precipitate major changes at an agency under constant and intense scrutiny.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
Chemistry World August 10, 2007 Hepeng Jia	China Invests More Than $1 Billion in Drug Safety In a bid to improve its food and drug safety, China has announced it will invest 8.8 billion yuan (US$1.16 billion) in the coming four years to improve its food and drug inspection and monitoring infrastructure.
BusinessWeek December 13, 2004 John Carey	How To Prevent Another Vioxx The tragedy should spur Congress and the FDA to improve the safety of new drugs.
The Motley Fool January 8, 2008 Brian Orelli	Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
BusinessWeek October 25, 2004 Gene G. Marcial	Par: Out Of The Rough? Since posting disappointing earnings in April, Par Pharmaceutical, No. 6 in U.S. generic drugs, has seen its shares plummet from 61 to 34.
Chemistry World August 2, 2007 Victoria Gill	Europe Poised for a Surge in Generic Drugs The European Medicines Agency's Committee for Medicinal Products for Human use has recommended the approval of a schizophrenia treatment which is the first generic drug to be assessed under Europe's centralized procedure.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
Chemistry World May 30, 2007 Hepeng Jia	Disgraced Drug Chief Sentenced to Death As China battles to root out corruption from its pharmaceutical sector, the former head of the State Food and Drug Agency, Zheng Xiaoyu, has been sentenced to death after being found guilty of taking bribes.
The Motley Fool March 3, 2009 Brian Orelli	Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think.
Chemistry World July 11, 2012 Ling Wang	China Targets Patented Drugs with Law Change China has altered its licensing laws to allow domestic pharmaceutical companies to make cheap generic copies of patented drugs under certain circumstances.
The Motley Fool December 10, 2008 Brian Orelli	Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline.
The Motley Fool January 20, 2005 Stephen D. Simpson	Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.
Pharmaceutical Executive October 1, 2011 Jill Wechsler	At the Helm of Industry As the lead FDA official overseeing the testing and approval of new drugs and biotech therapies for some 20 years, Dr. Janet Woodcock has built a robust and modern drug regulatory system.
Chemistry World August 21, 2013 Phillip Broadwith	Two way traffic for Chinese drug licensing Chinese companies have trailed behind their Western counterparts in developing innovative new drugs. Very few of those inventions have been considered useful enough to be licensed by western companies. However, that appears to be changing.
The Motley Fool June 30, 2005 Brian Gorman	The Co-Pay Effect Higher co-payments look like the wave of the future, and investors should expect the trend to boost major generic players like Teva Pharmaceutical, Mylan Laboratories, and Novartis.
Managed Care May 2006 John Carroll	Effective Ways To Increase Usage of Generics Generics is one of the few areas where insurance plans can economize effectively. BlueCross & BlueShield of North Carolina is one of many insurers that are changing members' and prescribers' behavior.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
Managed Care July 2005	Cost being equal, consumers prefer older drugs Seven out of 10 consumers would prefer a drug that had been on the market for 10 years or more, compared to a newer drug, even if the copayments were equal. This could be a sign that consumers are more inclined to start using generic medications.
The Motley Fool April 7, 2011 Brandon Glenn	"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.
The Motley Fool January 25, 2006 Stephen D. Simpson	Bristol-Myers Catches a Cold Tough days are coming, but so are promising new drugs. It's understandable why long-term investors might be willing to hold on and see how things work out.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
Chemistry World February 19, 2015 Phillip Broadwith	Generic: the unbranding of modern medicine Jeremy Greene's book documents the evolution of generic drugs in the pharmaceutical marketplace, considering the interplay of scientific, regulatory, legal and political forces that shaped the path to modern healthcare systems.
The Motley Fool March 15, 2005 Stephen D. Simpson	IVAX Is No Placebo The maker of generic drugs moves higher on fourth-quarter results that surprised Wall Street.